Introduction Laparoscopic adjustable gastric band (LAGB)-related complications have been reported in significant numbers of patients often leading to band removal. Increasingly revisional bariatric surgery (RBS) is offered, most commonly either band to Roux-en-Y gastric bypass (B-RYGB) or band to sleeve gastrectomy (B-SG). Objectives We conducted a systematic review and metaanalysis of studies to evaluate the efficacy of RBS following failed LAGB. Methods Medline, Embase, The Cochrane Library and NHS Evidence were searched for English language studies assessing patients who had undergone LAGB and who subsequently underwent either B-RYGB or B-SG. Results Thirty-six studies met the inclusion criteria. There were 2617 patients. B-RYGB was performed in 60.5% (n = 1583). There was one death within 30 days (0.0004%). The overall pooled morbidity rate was 13.2%. There was no difference between the B-RYGB and B-SG groups in morbidity, leak rate or return to theatre. Percentage excess weight loss (%EWL) following the revisional procedure for all patients combined at 6, 12 and 24 months was 44.5, 55.7 and 59.7%, respectively. There was no statistical difference in %EWL between B-RYGB and B-SG at any time point. The rates of remission of diabetes, hypertension and obstructive sleep apnoea were 46.5, 35.9 and 80.8%, respectively. Conclusions Randomised controlled trials (RCTs) do not exist on this issue but the available observational evidence does suggest that RBS is associated with generally good outcomes similar to those experienced after primary surgery. Further, high-quality research, particularly RCTs, is required to assess long-term weight loss, comorbidity and quality of life outcomes.
Introduction
The prevalence of obesity worldwide continues to grow and is a significant burden on individuals and healthcare systems. Bariatric surgery is the most effective treatment option that results in significant long-term sustainable weight loss [1] [2] [3] . The laparoscopic adjustable gastric band (LAGB) was the first bariatric procedure to gain widespread acceptance due to its AAT and RS contribute equally as joint senior authors.
good weight loss results in the short term, its relative simplicity and low early complication rates [4] . However, randomised and non-randomised studies have shown that Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are superior to LAGB in terms of weight loss and impact on obesityrelated comorbidities [5] [6] [7] . As a result, there has been a significant fall worldwide in the number of LAGBs performed in favour of RYGB and SG [8] [9] [10] .
The rate of LAGB-related complications such as band erosion, band slippage, oesophageal dilatation and dysmotility and tube or port dysfunction can be as high as 15-58% often leading to band removal [11] [12] [13] [14] [15] . In addition, a substantial proportion of patients fail to lose sufficient weight with LAGB alone [12, 16] ; in one study, insufficient weight loss (defined as percentage excess weight loss (%EWL) of <25%) was reported in 10.5% of patients at 5 years [13] .
Increasingly therefore, revisional bariatric surgery (RBS) is being performed to remove the gastric band and convert to another bariatric procedure, most commonly RYGB or SG. Previous systematic reviews have demonstrated both the safety and efficacy of RBS [17] [18] [19] . Despite this, the efficacy of RBS in terms of weight loss might be inferior to primary bariatric surgery (PBS) and the complication rates higher [17, 20, 21] . However, the choice that patients and clinicians face is not between RBS and PBS but between RBS and medical management in patients who have already undergone LAGB. Patients requiring RBS are different to those undergoing PBS; they have by definition failed a primary bariatric surgical intervention for a variety of reasons which might put them at higher risk for a further revisional procedure. Therefore, direct comparison of RBS with PBS is not necessarily of great relevance.
In addition, whilst the impact of PBS on obesity-related comorbidities is well established, the impact of RBS on these comorbidities is far less certain [22] [23] [24] [25] [26] .
Obesity has a negative impact upon quality of life (QOL) [27] , and there is increasing evidence that QOL can be improved significantly following bariatric surgery [28] [29] [30] [31] . It is tempting to extrapolate the positive impact that PBS has been shown to have on QOL and hypothesise that RBS if achieving similar levels of weight loss and comorbidity improvement should result in similar QOL improvements. However, patients undergoing RBS are likely to have different characteristics to patients receiving bariatric surgery for the first time. It is possible that some of those physical, psychological or social factors have contributed to the failure of their initial LAGB and therefore may be more resistant to treatment. Indeed, there is much evidence to suggest that psychological and social factors, both preoperative and postoperatively, are predictive of poorer outcomes following bariatric surgery [32] [33] [34] [35] [36] [37] .
Hence, we aimed to conduct a systematic review and metaanalysis of observational and interventional studies to evaluate the efficacy and safety of revisional bariatric surgery (RYGB and SG) following a failed LAGB in regard to complication rates, weight loss, resolution of obesity-related comorbidities and QOL.
Methods
A systematic review and meta-analysis was performed. This was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) recommendations [38] .
Eligibility Criteria
English language, prospective and retrospective, observational and interventional studies were included. Studies were included if they: (1) included patients who had undergone PBS in the form of a gastric band and who subsequently underwent RBS: either a gastric band converted to RYGB (B-RYGB) or a gastric band converted to SG (B-SG); (2) presented data on one or more of the following postoperatively: weight change at a minimum of 6 months, obesity-related comorbidities at any time point or quality of life data at any time point; and (3) included more than 10 patients. Studies including patients undergoing other types of revisional procedure (e.g. revisions of vertical banded gastroplasty, revisions of sleeve gastrectomy or gastric band revisions not in the form of either B-RYGB or B-SG) were excluded unless the data regarding B-RYGB and B-SG was clearly separable from other data. Other exclusions included studies reporting on data from less than 10 patients and studies reporting data from open revisional procedures.
Information Sources and Search Strategy
A literature search was performed using Medline, Embase, The Cochrane Library and NHS Evidence up to November 2015. The search was performed using combinations of keywords: laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, laparoscopic Roux-en-Y gastric bypass, revision, revisional, reoperation, salvage, rescue, repeat, weight loss, postoperative complication, surgical complication, morbidity, mortality, quality of life and comorbidities. The exact search strategy can be seen in Appendix 1. In addition to the above databases, the reference lists of included studies were also searched manually for additional studies.
Study Selection
Studies identified by the search strategy above were screened for inclusion using a two-step process. Firstly, the titles and abstracts of each study were assessed (AS and VC), if these were felt to be relevant, then the full text or the paper was accessed. Secondly, the full text was assessed for the inclusion and exclusion criteria listed above (AS and VC). Differences between the assessors were resolved by discussion and mutual agreement.
Data Collection
Data collected included study design, the inclusion and exclusion criteria of each study, sample size, demographic data, preand postoperative body mass index (BMI) and/or weight, length of hospital stay (LOS), operative time, postoperative morbidity and mortality, length of follow-up, %EWL, comorbidity resolution or improvement and QOL data.
Where %EWL was not explicitly stated, this was, where possible, calculated using the formula: postoperative weight loss / (preoperative weight-ideal body weight). The weight at which a BMI of 25 would be obtained was used as the ideal body weight. [39] .
Summary Measures and Synthesis of Results
Stats Direct version 3.0.141 (StatsDirect Ltd., Altrincham, UK) was used to analyse data. Mean values for follow-up, operation time and LOS were combined and expressed using weighted means. Meta-analysis of effect size, forest plots, relative risk and pooled prevalence data were calculated using the Dersimonian-Laird random effects model [40] . A p value of less than 0.05 was considered statistically significant. Heterogeneity was expressed using I
2
, where values of 25, 50 and 75% correspond to cut-off points for low, moderate and high degrees of heterogeneity [41] .
Results

Study Selection
The literature search produced 358 results. Figure 1 shows the PRISMA flow diagram detailing the process of study selection. Ultimately the process produced 36 studies which were included in the final analysis [15, . Table 1 describes the study designs and population characteristics of the included studies.
Study Characteristics
Out of 36 studies, eight studies [43, 46, 47, 52, 57, 60, 62, 76] reported patients undergoing B-RYGB and B-SG separately. In total, therefore, there were 44 data sets. The 36 studies included a total sample of 2617 patients (2144 females, 415 males, two studies did not state [52, 64] ). The smallest study included 10 patients (as per the inclusion criteria) [50] whilst the largest included 300 patients [65] . Twenty-six studies were retrospective and 10 were prospective studies. No controlled or randomised studies were identified. The earliest [38] study was published in 2003 [15] , whilst 61.0% (22 out of 36) were published in the last 5 years. Most revisional procedures were B-RYGB (n = 1583, 60.5%) whilst the remaining were B-SG (n = 1034, 39.5%). Women made up 83.8% (2144 of 2559) of the overall study population and the weighted mean age was 42.7. Further demographic data can be seen in Table 2. A one-stage procedure involves removal of the gastric band concomitantly with performance of RBS, whereas with a two-stage procedure, the band is removed and RBS performed at a subsequent date. In 10 studies [42, 45, 50, 54, 56, 58, 67, 71, 75, 76] , all patients underwent a one-stage conversion, and in three studies [46, 65, 69] , all patients underwent a two-stage Twenty-eight studies (2300 patients) reported their indications for revision ( Table 3 ). The most common indication for revision was insufficient weight loss. Most studies defined this as %EWL less than 25%; however, a number of studies did not provide a definition.
Twenty-four studies reported their mean length of followup. Weighted mean follow-up was 27.1 ± 10.0 months.
Synthesis of Results
Mortality and Morbidity
Thirty-four studies reported on mortality and only one death within 30 days was reported (0.0004%). Morbidity and postoperative complications were reported by 33 studies (Table 4 ). The overall pooled incidence of complications was 13.2% (95% CI 9.5-17.3%, I 2 = 87.1%, 32 studies). Seventeen studies broke complications down into early (less than 30 days) and late (greater than 30 days). The pooled early incidence of complications was 8.9% (95% CI 6.5-11.7%, I 2 = 56.6%) and the pooled late incidence of complications was 8.1% (95% CI 4.4-12.8%, I 2 = 85.5%). Anastomotic or staple line leak was reported in 2.0% (95% CI 1.5-2.7%, I 2 = 13.2%, 33 studies) and return to theatre in 5.4% (95% CI 3.4-7.8%, I 2 = 73.7%, 24 studies). The conversion rate to an open procedure was 1.2% (95% CI 0.7-1.9%, I 2 = 31.1%).
Results for separate pooled analysis of studies reporting RYGB and SG can be found in Table 5 .
A number of studies compared morbidity between groups undergoing B-RYGB and B-SG. Meta-analysis of these studies demonstrates that there was no difference between the groups in overall morbidity (RR 1. 69 None of the studies directly compared morbidity rates between one-and two-stage RBS. Pooling of the morbidity from the studies that did not mix one-and two-stage procedures suggests overall morbidity for RYGB was 10.0% (95% CI 5.7-15.2%, I 2 = 26.8%, 4 studies [42, 58, 71, 76] ) and 16.2% (1 study [46] ) in the one-and two-stage groups, respectively. For SG, the overall morbidity was 7.3% (95% CI 3.2-12.9%, I 2 = 60.3%, 6 studies [45, 50, 54, 67, 75, 76] ) and 6.6% (95% CI 0.5-19.1%, I 2 = 89.9%, 3 studies [46, 65, 69] ) in the one-and two-stage groups, respectively.
Operation Time
Twenty-six studies reported mean operative time. The weighted mean operative time was higher for B-RYGB than B-SG (152.8 ± 41.0 min vs 125.0 ± 16.1 min, p < 0.01).
Length of Stay
Twenty studies reported mean LOS. The weighted mean LOS was longer for B-RYGB patients than B-SG (5.2 ± 1.9 days vs 4.1 ± 1.5 days, p < 0.01). 
Comorbidity Outcomes
Definitions of what exactly constituted remission or improvement of a comorbidity varied between studies. For diabetes and hypertension, all studies defined remission as the cessation of medications and improvement as the reduction in dose or number of medications. However, whereas Moon et al. [62] required patients to achieve a fasting glucose level of <125 mg/dl or a blood pressure of <140/90 mmHg for diabetes and hypertension, respectively, other studies did not specify this. Robert et al. [68] simply required a normal HbA1C or blood pressure to be reached with no definition of what values they consider normal. The other studies [70, 75, 76] classified patients purely on the basis of their medications. Robert et al. [68] considered obstructive sleep apnea (OSA) to be in remission if patients achieved an apnea-hypopnea index (AHI) of <15. They considered improvement to be an AHI <30. Yazbek et al. [75] classified remission as a cessation of the use of continuous positive airway pressure (CPAP).
Comorbidity outcomes for individual studies can be seen in Table 10 . Five studies reported remission rates in patients with diabetes prior to their revisional procedure [62, 68, 70, 75, 76] . The pooled remission rate was 46.5% (95% CI 21.2-72.9%, I 2 = 83.5) among the 79 (pooled incidence of diabetes in these five studies was 19.9%, 95% CI 14.9-25.6%) patients with diabetes studied. Three studies reported that 84.0% (95% CI 51.5-99.7%, I 2 = 84.7%) of 52 (pooled incidence of diabetes = 21.4%, 95% CI 13.0-31.1%) patients achieved either remission or improvement [62, 68, 76] .
Of five studies, looking at 150 (pooled incidence of hypertension = 37.2%, 95% CI 30.9-43.9%) patients with hypertension, four reported on remission [62, 70, 75, 76] . Of these, 35.9% (95% CI 23.1-49.8%, I 2 = 57.8%) were considered to be in remission following revisional surgery. Three studies reported on remission or improvement and reported 71.6% (95% CI 54.5-86.0%, I 2 = 67.6%) of patients achieved either remission or an improvement in their hypertension [62, 68, 76] .
Only two studies reported improvement of OSA, demonstrating that 80.8% (95% CI 65.0-92.6%, I 2 = 0.0%) of patients improved or were cured [68, 75] .
Quality of Life
Only two studies looked at QOL outcomes [56, 68] . Kafri et al. [56] reported the extent to which patients agreed with four statements. They did not use a validated QOL measure. The study demonstrated that 73% of patients reported being happier, 63% reported feeling more attractive and 70% reported being satisfied with their appearance after their revisional surgery. However, only 22% were satisfied with the extent of their weight loss. Robert et al. [68] used the BAROS questionnaire [77] to assess QOL. They reported a mean 1.5 point gain in QOL following revisional surgery. 
Discussion
Revisional bariatric surgery is on the rise due to the rapid increase in patients undergoing bariatric surgery. Unfortunately, there is a relative lack of evidence to support the practice. Unlike PBS, for which there are now wellconducted longitudinal and randomised controlled trials (RCTs), our systematic review shows that the evidence for RBS is limited with no RCTs and many retrospective studies [1, [78] [79] [80] [81] .
The results of this systematic review suggest that both B-RYGB and B-SG are viable options for patients after failed LAGB. The pooled morbidity and mortality rates described in this systematic review are comparable to those reported for PBS and do not suggest that RBS is associated with a significant increase in morbidity rates [17] . Anastomotic or staple line leaks are the most feared complication following RBS. However, the pooled leak rate of 2.2% after B-SG is similar to that described by Aurora et al. in their systematic review of leak rates after primary SG [82] . Similarly, a leak rate of 1.8% after B-RYGB is similar to that reported for primary RYGB [17, 83] . Some authors have suggested that complication rates, particularly leak rates, may be higher after B-SG than after B-RYGB [44, 84] . However, this has not been seen in our results.
Our data suggests that surgeons are more hesitant about performing one-stage B-SG than B-RYGB. B-RYGB was significantly more likely to be performed in a single stage than B-SG in our analysis. This is potentially influenced by the fear of increased leak rates in B-SG as discussed above. The limited data we are able to present would suggest that one-stage procedures are not associated with higher morbidity.
Overall, these findings suggest that patients should expect a %EWL of 44.5, 55.7 and 59.7% at 6, 12 and 24 months, respectively. A number of systematic reviews analysing weight loss after PBS have reported %EWL of 61-70% [78, 85, 86] . However, such direct comparisons lack relevance due to the differences in the study populations. Nonetheless, the %EWL observed in this systematic review is clinically relevant and would have a significant impact on obesity-related comorbidities [87, 88] . It should be emphasised again that the choice facing patients and clinicians is not between PBS and RBS but between RBS and medical management. There does not appear to be a difference in %EWL outcomes between B-RYGB and B-SG but the number of studies is small and further research to assess which procedure is most effective is needed.
This systematic review shows that there is a paucity of evidence regarding the impact of RBS on obesity-related comorbidities. A small number of studies showed that a significant proportion of patients will notice an improvement in their diabetes, hypertension and OSA (84.0, 71.6 and 80.8%, respectively), which is similar to that reported following PBS [78, 85] . Although these results are promising, further studies are needed to assess and quantify the benefits that patients are able to achieve in their medical comorbidities following RBS. Our study identified only two studies which looked at QOL outcomes following RBS. Of these, only one [68] used a validated QOL assessment tool (the BAROS questionnaire). Their results did suggest an improvement in QOL after revisional surgery. It is important that QOL is assessed more rigorously in future studies.
Although the number of LAGB procedures performed is falling, large numbers of patients are living with a gastric band and more are being inserted each year [8] [9] [10] . Estimates suggest that 15-40% of patients will require revisional surgery after LAGB [5, 81, [89] [90] [91] . Therefore, it is likely that the number of patients with gastric bands presenting for consideration of RBS is likely to rise further over the next decade. It is critical therefore that high-quality evidence to guide practice is available and although interest in this area is growing (as evidenced by the increased number of recent studies in this review), good-quality evidence is still lacking. RBS is undoubtedly more technically challenging than PBS and therefore should be performed with caution, ideally in high-volume tertiary centres [92] . Although our results suggest that RBS can be associated with good outcomes, selection of patients for RBS after LAGB should still be carefully considered and take into account individual patient factors, preferences and reasons for failure of LAGB. This is not the first systematic review to focus on revisional surgery after LAGB. In 2013, Coblijn et al. [84] systematically reviewed the data for B-RYGB or B-SG after primary LAGB. They concentrated on postoperative morbidity rather than longer term weight loss and concluded that although revisional surgery was safe, it did carry a higher complication rate than primary procedures. Elnahas et al. [19] in 2012 reviewed the weight loss data for patients having RBS after primary LAGB. This study predates the majority of studies included in our review and the number of patients included was much smaller. The mean %EWL they describe is similar to our findings for B-RYGB; however, they describe a %EWL of only 22% for B-SG. In contrast, our findings do not suggest a difference, at least in the short term, in %EWL between B-RYGB and B-SG. Most recently, Mahawar et al. [17] performed a systematic review comparing revisional RYGB and SG to their respective primary procedures. Whilst they did not restrict themselves purely to revisions following LAGB, the majority of patients had undergone LAGB as their primary procedure. They concluded that RBS carried a higher complication rate than PBS. Although they did not perform meta-analysis on the weight loss data, they found that the majority of included studies reported inferior weight loss for RBS than PBS. Our study is more recent and therefore includes significantly more patients. In addition, none of the previous systematic reviews include data on comorbidity resolution and QOL in the analysis.
Our study has several limitations. The quality of any systematic review is limited by the quality of the included studies. None of the included studies were RCTs; all were observational studies of variable size, design and quality. Length of follow-up, outcome measures, surgical techniques and inclusion criteria all varied widely between studies. Although the overall number of patients was relatively large (2617), the Carandina [46] Gonzalez-Heredia [52] Favours SG Favours RYGB Favours SG Favours RYGB
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Conclusions
This study shows that the evidence for RBS, though limited and lacking in RCTs, suggests that RBS results in significant weight loss, obesity-related comorbidity resolution and has a positive impact on QOL, with an acceptable safety profile. Further, high-quality studies, particularly RCTs, are required to assess long-term efficacy and safety of RBS.
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